Press Releases

Novo Nordisk launches Levemir® in the United States (28 Mar 2006)

Dansk version
Read in PDF format

Novo Nordisk today announced that Levemir®, a long-acting basal insulin analogue, is now commercially available in the United States. Levemir® is indicated in the US for once- or twice-daily injection for the treatment of adults and children with type 1 diabetes and adults with type 2 diabetes. The relatively flat action profile of Levemir® offers patients up to 24 hours of blood glucose control.

“Diabetes is currently one of the most serious health challenges affecting people worldwide with millions of Americans living with diabetes in poor control.  The availability of Levemir® offers patients an important new long-acting insulin analogue with effective glycaemic control – while addressing physician and patient concerns of weight gain and hypoglycaemia. Accuracy and ease-of-use can be obtained with Levemir® in FlexPen®, the convenient insulin delivery system," said Martin Soeters, president of Novo Nordisk Inc, Novo Nordisk’s US affiliate. “As the world’s leading provider of insulin, we are dedicated to improving diabetes care, and with the addition of Levemir® are proud to be the first and only company in the US offering a complete portfolio of insulin analogues to meet individual patient needs.”

Levemir® is available in vials and Levemir® FlexPen®. FlexPen® is the preferred prefilled insulin pen by patients.[i],[ii]  

Levemir® was approved by the US Food and Drug Administration in June 2005 and is currently approved in 50 countries worldwide. 

Novo Nordisk portfolio of analogue products includes Levemir®, a long-acting insulin analogue; NovoRapid®, a fast-acting insulin analogue, and NovoMix® 30, a premixed insulin analogue.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 22,000 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.

For further information please contact:

Media:

Investors:

 

 

Outside North America:

Outside North America:

Elin K Hansen

Mogens Thorsager Jensen

Tel: (+45) 4442 3450

Tel: (+45) 4442 7945

 

 

 

Christian Qvist Frandsen

 

Tel: (+45) 4443 5182

 

 

In North America:

In North America:

Susan T Jackson

Mads Veggerby Lausten

Tel: (+1) 609 919 7776

Tel: (+1) 609 919 7937

 

[i] Niskanen L, Jensen LE, Råstam J, Nygaard-Pedersen L, Erichsen K, Vora JP. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clinical Therapeutics 2004:26 [no 4]:531-540.

[ii]   IMS Health, data collected for the 12 months ending September 2005.

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •